FrontWell Solutions and ValGenesis Announce Strategic Alliance

July 23, 2024 by
FrontWell Solutions GmbH, Julia Tantzky

PRESS RELEASE

ValGenesis and FrontWell Solutions Announce Strategic Alliance


Santa Clara, July 23, 2024,
ValGenesis, Inc.
ValGenesis Inc., a market leader in enterprise validation lifecycle management systems (VLMS), and FrontWell Solutions, a systems integrator and consulting firm headquartered in Germany, have established a strategic alliance to empower life sciences companies to contribute to advancements in healthcare and drug development through digital validation solutions.

Founded in 2017, FrontWell is a company focused on manufacturing digitization for regulated industries. Services include consulting, software selection, business process analysis, system integration, validation, and support operations. With offices in 4 countries, FrontWell is a trusted partner for the pharmaceutical, biotech, and medical device industries, providing manufacturing digitization services to 12 of the top 20 life sciences companies.

ValGenesis is the industry innovator of digitized validation. The company’s platform, which includes its flagship VLMS offering, is used in over 100,000 GMP systems worldwide, helping life sciences companies advance their digital transformation strategy, enforce compliance, and enable standardization with 100% digital, risk-based validation software.

Both companies prioritize regulatory compliance, efficiency, and quality in life sciences. FrontWell’s expertise complements ValGenesis’ digital transformation capabilities via ValGenesis VLMS—a unified, risk-based, data-centric platform that digitizes the entire GxP software validation lifecycle, ensuring compliant and optimized manufacturing processes.

ValGenesis and FrontWell Solutions collaborate to empower life sciences organizations, driving excellence in manufacturing and validation. This benefits patient safety and fosters innovation,” explains Bo Olsen, ValGenesis’ SVP of Partners. “As global leaders shaping the industry’s digital future, we provide customers with a curated portfolio of industry-leading validation software solutions and best-in-class tools for every stage of their manufacturing process. We’re excited about the partnership’s potential and our strengthened presence in Europe.

Validation lifecycle management, a cornerstone of every project we deliver to our valued clients in the GxP environment, is further strengthened by our strategic partnership with ValGenesis, the market-leading VLMS software provider. We are both humbled and excited about this collaboration as it underscores our ambition and vision to be forerunners in shaping the digital future of life sciences, bringing significant benefits to our customers,” said Ardavan Heidari, CEO of FrontWell.

ABOUT FRONTWELL SOLUTIONS
FrontWell Solutions is a reputable consulting firm and systems integrator that specializes in MES, MOM, LIMS, and Manufacturing/Laboratory Analytics. Their expertise lies in providing manufacturing digitalization services to the leading pharmaceutical and biotechnology companies, specifically 12 out of the top 20.  With their vast experience in pharma, biotech, and medical device production, as well as system integration, software product development, and IT/OT manufacturing operations, FrontWell possesses a diverse and unparalleled skill set.  

-MORE-
Known for their outstanding performance, FrontWell is committed to assisting clients in accomplishing their manufacturing digitalization objectives. For more information, visit https://www.frontwell-solutions.com/

ABOUT VALGENESIS INC.
ValGenesis, Inc. is the creator of an innovative software platform that serves as a foundation for managing compliance-based validation activities in life science companies. ValGenesis, Inc. is the provider of the first enterprise application that manages the corporate validation lifecycle process. This solution is fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. As the first fully paperless solution for electronic management of validation execution and approval, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award in 2005. For more information, visit https://www.valgenesis.com/


Further Information
Althea D’Sylva, ValGenesis Communications
+1 510-445-0505 Ex. 1026
althea.dsylva@valgenesis.com 

Julia Tantzky, FrontWell Solutions Communications
+49 170 178 95 19,
julia.tantzky@frontwell-solutions.com

in News
FrontWell Solutions GmbH, Julia Tantzky July 23, 2024
Share this post
Tags
Archive